Home  |  Contact

Cellosaurus MIA PaCa-2 GR800 (CVCL_WI25)

[Text version]

Cell line name MIA PaCa-2 GR800
Synonyms MiaPaCa-2 GR800
Accession CVCL_WI25
Resource Identification Initiative To cite this cell line use: MIA PaCa-2 GR800 (RRID:CVCL_WI25)
Comments Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
Sequence variations Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0428 (MIA PaCa-2)
Sex of cell Male
Age at sampling 65Y
Category Cancer cell line
Publications

PubMed=25485960; DOI=10.4161/15384047.2014.986967
Samulitis B.K., Pond K.W., Pond E., Cress A.E., Patel H., Wisner L., Patel C., Dorr R.T., Landowski T.H.
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Cancer Biol. Ther. 16:43-51(2015)

Cross-references
Other Wikidata; Q95989683
Entry history
Entry creation24-May-2019
Last entry update20-May-2021
Version number5